| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 2 securities · may seek to influence control | ||||||
|
Essa Pharma, Inc.
13D/A
EPIX · 29668H708
|
9.8% |
7/21/2025
Event 7/17/2025
|
||||
| Soleus Capital Master Fund, L.P. | 9.8% | |||||
| Soleus Capital, LLC | 9.8% | |||||
| Soleus Capital Group, LLC | 9.8% | |||||
| Soleus Capital Management, L.P. | 9.8% | |||||
| Soleus GP, LLC | 9.8% | |||||
| Guy Levy | 9.8% | |||||
|
Theratechnologies Inc.
13D/A
THTX · 88338H704
|
10.4% |
4/11/2025
Event 4/11/2025
|
||||
| Soleus Capital Master Fund, L.P. | 10.4% | |||||
| Soleus Capital, LLC | 10.4% | |||||
| Soleus Capital Group, LLC | 10.4% | |||||
| Soleus Capital Management, L.P. | 10.4% | |||||
| Soleus GP, LLC | 10.4% | |||||
| Guy Levy | 10.4% | |||||
| Schedule 13G · 27 securities · passive | ||||||
|
Evolus, Inc.
13G
EOLS · 30052C107
|
5.3% |
8/31/2026
Event 8/27/2026
|
||||
| Soleus Capital Master Fund, L.P. | 5.3% | |||||
| Soleus Capital, LLC | 5.3% | |||||
| Soleus Capital Group, LLC | 5.3% | |||||
| Soleus Capital Management, L.P. | 5.3% | |||||
| Soleus GP, LLC | 5.3% | |||||
| Guy Levy | 5.3% | |||||
|
Processa Pharmaceuticals, Inc.
13G
PCSA · 74275C403
|
5.8% |
8/18/2026
Event 8/3/2026
|
||||
| Soleus Capital Master Fund, L.P. | 5.8% | |||||
| Soleus Capital, LLC | 5.8% | |||||
| Soleus Capital Group, LLC | 5.8% | |||||
| Soleus Capital Management, L.P. | 5.8% | |||||
| Soleus GP, LLC | 5.8% | |||||
| Guy Levy | 5.8% | |||||
|
Palisade Bio, Inc.
13G/A
PALI · 696389402
|
7.5% |
8/13/2026
Event 6/30/2026
|
||||
| Soleus Capital Master Fund, L.P. | 7.5% | |||||
| Soleus Capital, LLC | 7.5% | |||||
| Soleus Capital Group, LLC | 7.5% | |||||
| Soleus Capital Management, L.P. | 7.5% | |||||
| Soleus GP, LLC | 7.5% | |||||
| Guy Levy | 7.5% | |||||
|
Inspire Medical Systems, Inc.
13G/A
INSP · 457730109
|
6.7% |
8/13/2026
Event 6/30/2026
|
||||
| Soleus Capital Master Fund, L.P. | 6.7% | |||||
| Soleus Capital, LLC | 6.7% | |||||
| Soleus Capital Group, LLC | 6.7% | |||||
| Soleus Capital Management, L.P. | 6.7% | |||||
| Soleus GP, LLC | 6.7% | |||||
| Guy Levy | 6.7% | |||||
|
Immunic, Inc.
13G/A
IMUX · 4525EP200
|
4.9% |
8/13/2026
Event 6/30/2026
|
||||
| Soleus Capital Master Fund, L.P. | 4.9% | |||||
| Soleus Capital, LLC | 4.9% | |||||
| Soleus Capital Group, LLC | 4.9% | |||||
| Soleus Capital Management, L.P. | 4.9% | |||||
| Soleus GP, LLC | 4.9% | |||||
| Guy Levy | 4.9% | |||||
|
Rigel Pharmaceuticals, Inc.
13G/A
RIGL · 766559702
|
9.9% |
8/13/2026
Event 6/30/2026
|
||||
| Soleus Capital Master Fund, L.P. | 9.9% | |||||
| Soleus Capital, LLC | 9.9% | |||||
| Soleus Capital Group, LLC | 9.9% | |||||
| Soleus Capital Management, L.P. | 9.9% | |||||
| Soleus GP, LLC | 9.9% | |||||
| Guy Levy | 9.9% | |||||
|
Cerus Corp
13G/A
CERS · 157085101
|
1.2% |
8/13/2026
Event 6/30/2026
|
||||
| Soleus Capital Master Fund, L.P. | 1.2% | |||||
| Soleus Capital, LLC | 1.2% | |||||
| Soleus Capital Group, LLC | 1.2% | |||||
| Soleus Capital Management, L.P. | 1.2% | |||||
| Soleus GP, LLC | 1.2% | |||||
| Guy Levy | 1.2% | |||||
|
Vericel Corp
13G/A
VCEL · 92346J108
|
2.8% |
8/13/2026
Event 6/30/2026
|
||||
| Soleus Capital Master Fund, L.P. | 2.8% | |||||
| Soleus Capital, LLC | 2.8% | |||||
| Soleus Capital Group, LLC | 2.8% | |||||
| Soleus Capital Management, L.P. | 2.8% | |||||
| Soleus GP, LLC | 2.8% | |||||
| Guy Levy | 2.8% | |||||
|
Biodesix Inc
13G
BDSX · 09075X207
|
5.1% |
6/18/2026
Event 6/17/2026
|
||||
| Soleus Capital Master Fund, L.P. | 5.1% | |||||
| Soleus Capital, LLC | 5.1% | |||||
| Soleus Capital Group, LLC | 5.1% | |||||
| Soleus Capital Management, L.P. | 5.1% | |||||
| Soleus GP, LLC | 5.1% | |||||
| Guy Levy | 5.1% | |||||
|
NovoCure Limited
13G/A
NVCR · G6674U108
|
9.1% |
5/8/2026
Event 3/31/2026
|
||||
| Soleus Capital Master Fund, L.P. | 9.1% | |||||
| Soleus Capital, LLC | 9.1% | |||||
| Soleus Capital Group, LLC | 9.1% | |||||
| Soleus Capital Management, L.P. | 9.1% | |||||
| Soleus GP, LLC | 9.1% | |||||
| Guy Levy | 9.1% | |||||
|
Jasper Therapeutics, Inc.
13G/A
JSPR · 471871202
|
1.0% |
5/8/2026
Event 3/31/2026
|
||||
| Soleus Capital Master Fund, L.P. | 0.4% | |||||
| Soleus Private Equity Fund III, L.P. | 0.6% | |||||
| Soleus Private Equity GP III, LLC | 0.6% | |||||
| Soleus PE GP III, LLC | 0.6% | |||||
| Soleus Capital, LLC | 0.4% | |||||
| Soleus Capital Group, LLC | 0.4% | |||||
| Soleus Capital Management, L.P. | 1.0% | |||||
| Soleus GP, LLC | 1.0% | |||||
| Guy Levy | 1.0% | |||||
|
Geron Corporation
13G/A
GERN · 374163103
|
6.5% |
5/8/2026
Event 3/31/2026
|
||||
| Soleus Capital Master Fund, L.P. | 6.5% | |||||
| Soleus Capital, LLC | 6.5% | |||||
| Soleus Capital Group, LLC | 6.5% | |||||
| Soleus Capital Management, L.P. | 6.5% | |||||
| Soleus GP, LLC | 6.5% | |||||
| Guy Levy | 6.5% | |||||
|
Context Therapeutics Inc.
13G/A
CNTX · 21077P108
|
7.6% |
5/8/2026
Event 3/31/2026
|
||||
| Soleus Capital Master Fund, L.P. | 7.6% | |||||
| Soleus Capital, LLC | 7.6% | |||||
| Soleus Capital Group, LLC | 7.6% | |||||
| Soleus Capital Management, L.P. | 7.6% | |||||
| Soleus GP, LLC | 7.6% | |||||
| Guy Levy | 7.6% | |||||
|
Pulmonx Corporation
13G
LUNG · 745848101
|
6.5% |
3/9/2026
Event 3/6/2026
|
||||
| Soleus Capital Master Fund, L.P. | 6.5% | |||||
| Soleus Capital, LLC | 6.5% | |||||
| Soleus Capital Group, LLC | 6.5% | |||||
| Soleus Capital Management, L.P. | 6.5% | |||||
| Soleus GP, LLC | 6.5% | |||||
| Guy Levy | 6.5% | |||||
|
Immunic, Inc.
13G
IMUX · 4525EP101
|
5.5% |
2/19/2026
Event 2/17/2026
|
||||
| Soleus Capital Master Fund, L.P. | 5.5% | |||||
| Soleus Capital, LLC | 5.5% | |||||
| Soleus Capital Group, LLC | 5.5% | |||||
| Soleus Capital Management, L.P. | 5.5% | |||||
| Soleus GP, LLC | 5.5% | |||||
| Guy Levy | 5.5% | |||||
|
C4 Therapeutics, Inc
13G/A
CCCC · 12529R107
|
10.0% |
2/12/2026
Event 12/31/2025
|
||||
| Soleus Private Equity Fund III, L.P. | 5.9% | |||||
| Soleus Private Equity GP III, LLC | 5.9% | |||||
| Soleus PE GP III, LLC | 5.9% | |||||
| Soleus Capital Master Fund, L.P. | 10.0% | |||||
| Soleus Capital, LLC | 10.0% | |||||
| Soleus Capital Group, LLC | 10.0% | |||||
| Soleus Capital Management, L.P. | 10.0% | |||||
| Soleus GP, LLC | 10.0% | |||||
| Guy Levy | 10.0% | |||||
|
Terns Pharmaceuticals, Inc.
13G/A
TERN · 880881107
|
0.2% |
2/12/2026
Event 12/31/2025
|
||||
| Soleus Capital Master Fund, L.P. | 0.2% | |||||
| Soleus Capital, LLC | 0.2% | |||||
| Soleus Capital Group, LLC | 0.2% | |||||
| Soleus Capital Management, L.P. | 0.2% | |||||
| Soleus GP, LLC | 0.2% | |||||
| Guy Levy | 0.2% | |||||
|
Organogenesis Holdings Inc.
13G/A
ORGO · 68621F102
|
7.9% |
2/12/2026
Event 12/31/2025
|
||||
| Soleus Capital Master Fund, L.P. | 7.9% | |||||
| Soleus Capital, LLC | 7.9% | |||||
| Soleus Capital Group, LLC | 7.9% | |||||
| Soleus Capital Management, L.P. | 7.9% | |||||
| Soleus GP, LLC | 7.9% | |||||
| Guy Levy | 7.9% | |||||
|
Surmodics, Inc.
13G/A
SRDX · 868873100
|
0% |
11/7/2025
Event 9/30/2025
|
||||
| Soleus Capital Master Fund, L.P. | 0% | |||||
| Soleus Capital, LLC | 0% | |||||
| Soleus Capital Group, LLC | 0% | |||||
| Soleus Capital Management, L.P. | 0% | |||||
| Soleus GP, LLC | 0% | |||||
| Guy Levy | 0% | |||||
|
STAAR Surgical Company
13G/A
STAA · 852312305
|
1.0% |
11/7/2025
Event 9/30/2025
|
||||
| Soleus Capital Master Fund, L.P. | 1.0% | |||||
| Soleus Capital, LLC | 1.0% | |||||
| Soleus Capital Group, LLC | 1.0% | |||||
| Soleus Capital Management, L.P. | 1.0% | |||||
| Soleus GP, LLC | 1.0% | |||||
| Guy Levy | 1.0% | |||||
|
Mural Oncology plc
13G/A
MURA · G63365103
|
0% |
11/7/2025
Event 9/30/2025
|
||||
| Soleus Capital Master Fund, L.P. | 0% | |||||
| Soleus Capital, LLC | 0% | |||||
| Soleus Capital Group, LLC | 0% | |||||
| Soleus Capital Management, L.P. | 0% | |||||
| Soleus GP, LLC | 0% | |||||
| Guy Levy | 0% | |||||
|
UroGen Pharma Ltd.
13G/A
URGN · M96088105
|
4.7% |
8/5/2025
Event 6/30/2025
|
||||
| Soleus Capital Master Fund, L.P. | 4.7% | |||||
| Soleus Capital, LLC | 4.7% | |||||
| Soleus Capital Group, LLC | 4.7% | |||||
| Soleus Capital Management, L.P. | 4.7% | |||||
| Soleus GP, LLC | 4.7% | |||||
| Guy Levy | 4.7% | |||||
|
Neuropace, Inc.
13G/A
NPCE · 641288105
|
7.0% |
8/5/2025
Event 6/30/2025
|
||||
| Soleus Private Equity Fund I, L.P. | 0.9% | |||||
| Soleus Private Equity GP I, LLC | 0.9% | |||||
| Soleus PE GP I, LLC | 0.9% | |||||
| Soleus Capital Master Fund, L.P. | 6.1% | |||||
| Soleus Capital, LLC | 6.1% | |||||
| Soleus Capital Group, LLC | 6.1% | |||||
| Soleus Capital Management, L.P. | 7.0% | |||||
| Soleus GP, LLC | 7.0% | |||||
| Guy Levy | 7.0% | |||||
|
Praxis Precision Medicines, Inc
13G/A
PRAX · 74006W207
|
4.6% |
8/5/2025
Event 6/30/2025
|
||||
| Soleus Capital Master Fund, L.P. | 4.6% | |||||
| Soleus Capital, LLC | 4.6% | |||||
| Soleus Capital Group, LLC | 4.6% | |||||
| Soleus Capital Management, L.P. | 4.6% | |||||
| Soleus GP, LLC | 4.6% | |||||
| Guy Levy | 4.6% | |||||
|
AxoGen, Inc.
13G/A
AXGN · 05463X106
|
3.7% |
5/2/2025
Event 3/31/2025
|
||||
| Soleus Capital Master Fund, L.P. | 3.7% | |||||
| Soleus Capital, LLC | 3.7% | |||||
| Soleus Capital Group, LLC | 3.7% | |||||
| Soleus Capital Management, L.P. | 3.7% | |||||
| Soleus GP, LLC | 3.7% | |||||
| Guy Levy | 3.7% | |||||
|
Verastem, Inc.
13G/A
VSTM · 92337C203
|
7.3% |
2/11/2025
Event 12/31/2024
|
||||
| Soleus Private Equity Fund III, L.P. | 3.9% | |||||
| Soleus Private Equity GP III, LLC | 3.9% | |||||
| Soleus PE GP III, LLC | 3.9% | |||||
| Soleus Capital Master Fund, L.P. | 3.5% | |||||
| Soleus Capital, LLC | 3.5% | |||||
| Soleus Capital Group, LLC | 3.5% | |||||
| Soleus Capital Management, L.P. | 7.3% | |||||
| Soleus GP LLC | 7.3% | |||||
| Guy Levy | 7.3% | |||||
|
Celcuity Inc.
13G/A
CELC · 15102K100
|
9.9% |
2/11/2025
Event 12/31/2024
|
||||
| Soleus Private Equity Fund II, L.P. | 4.6% | |||||
| Soleus Private Equity GP II, LLC | 4.6% | |||||
| Soleus PE GP II, LLC | 4.6% | |||||
| Soleus Capital Master Fund, L.P. | 9.9% | |||||
| Soleus Capital, LLC | 9.9% | |||||
| Soleus Capital Group, LLC | 9.9% | |||||
| Soleus Capital Management, L.P. | 9.9% | |||||
| Soleus GP LLC | 9.9% | |||||
| Guy Levy | 9.9% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.